Anti-CD19 mAb modified mesoporous titanium dioxide as exclusively targeting vector for efficient B-lymphoblastic...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• B-cell lymphoblastic leukemia (B-LL) is a significant cause of cancer death in children and adolescents.
• The CD19 surface marker is a specific target for B-LL immunotherapy.
• Existing treatments face challenges, necessitating novel therapeutic strategies.

Purpose of the Study:

• To design and evaluate a mesoporous titanium dioxide nanoparticle (MTN)-based drug delivery system for B-LL treatment.
• To conjugate anti-CD19 monoclonal antibody to PEGylated MTNs loaded with doxorubicin (DOX).
• To assess the efficacy and safety of the CD19-PEG-MTN/DOX nanodrug on B-LL cells.

Main Methods:

• Conjugation of anti-CD19 antibody to PEGylated MTNs and loading with doxorubicin (DOX).
• In vitro evaluation of CD19-PEG-MTN/DOX on CD19+ B-LL cell lines (KOPN 8, NALM-6) and CD19-negative cell line (U937).
• Analysis of apoptosis-related protein expression (Bax, Caspase-3, Bcl2, MCL-1, HSP 70, BAG 3) and assessment of cytotoxicity and biocompatibility.

Main Results:

• CD19-PEG-MTN/DOX nanoparticles specifically recognized and induced apoptosis in CD19+ B-LL cell lines.
• Treatment upregulated pro-apoptotic proteins (Bax, Caspase-3) and downregulated anti-apoptotic proteins (Bcl2, MCL-1, HSP 70, BAG 3) in B-LL cells.
• The nanodrug showed no significant effect on CD19-negative cells (U937) and exhibited low cytotoxicity with good biocompatibility.

Conclusions:

• CD19-PEG-MTN/DOX is an effective targeted nanodrug for B-LL treatment.
• The nanodrug induces apoptosis in B-LL cells via modulation of key apoptotic proteins.
• This targeted nanoparticle system demonstrates potential as a safe and effective therapeutic agent for B-cell lymphoblastic leukemia.